(Reuters) - Novartis said on Friday the U.S. Food and Drug Administration watchdog had asked it to suspend marketing and sales of the drug because clinical trial data indicated a possible link to heart attacks and strokes.
As a consequence, the group cut its outlook for net sales growth for 2007 to above five percent, and for the pharmaceuticals division to a low- to mid-single-digit percentage.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment